Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- GSK Enters Urology Market with Avolve
September 21, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 21, 2009
- Asahi Kasei Aims at Sales of ¥100 Bil. in FY2015
September 21, 2009
- Chugai to Import Tamiflu for Additional 12 Mil. Persons
September 21, 2009
- BUSINESS NEWS IN BRIEF
September 21, 2009
- GSK to Supply Relenza for 13.5 Mil. Persons
September 21, 2009
- Olmetec Ranked No. 1 among ARBs in MR Activity Assessment: So-net M3
September 21, 2009
- NHO to Standardize Healthcare Services Using Its Own Database
September 21, 2009
- Fukuoka Pref. to Start Model Project to Promote Use of Generics
September 21, 2009
- Norvasc Most Reliable Antihypertensive: Nextit Research
September 21, 2009
- Novartis to Conduct Clinical Trial for Flu Vaccine in Japan
September 21, 2009
- Eli Lilly Japan to Achieve Sales of US$1 Bil. This Year
September 21, 2009
- NEW PRODUCTS
September 21, 2009
- ESC Congress in Barcelona
September 21, 2009
- R&D NEWS IN BRIEF
September 21, 2009
- China's Essential Drug List May Hit Non-Chinese Drug Firms Operating in China
September 14, 2009
- JPA Member Pharmacies Continue to Sell OTC Drugs by Phone: Kenko.com
September 14, 2009
- Yano Research Predicts 6-9% NHI Price Cuts in April 2010
September 14, 2009
- Need for Importing New-Type Flu Vaccines Questioned
September 14, 2009
- Blopress Ranked as Best-Selling Drug in Japan in 1st Qtr: IMS Japan
September 14, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…